153 related articles for article (PubMed ID: 23313659)
1. RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia.
Yang X; Qian J; Sun A; Lin J; Xiao G; Yin J; Chen S; Wu D
Clin Biochem; 2013 May; 46(7-8):579-83. PubMed ID: 23313659
[TBL] [Abstract][Full Text] [Related]
2. RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.
Sano H; Shimada A; Taki T; Murata C; Park MJ; Sotomatsu M; Tabuchi K; Tawa A; Kobayashi R; Horibe K; Tsuchida M; Hanada R; Tsukimoto I; Hayashi Y
Int J Hematol; 2012 May; 95(5):509-15. PubMed ID: 22407852
[TBL] [Abstract][Full Text] [Related]
3. The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia.
Yang J; Yao DM; Ma JC; Yang L; Guo H; Wen XM; Xiao GF; Qian Z; Lin J; Qian J
Tumour Biol; 2016 Aug; 37(8):10107-14. PubMed ID: 26820131
[TBL] [Abstract][Full Text] [Related]
4. [C-kit, NPM1 and FLT3 gene mutation patterns and their prognostic significance in 656 Chinese patients with acute myeloid leukemia].
Ding ZX; Shen HJ; Miao JC; Chen SN; Qiu QC; Qi XF; Jin ZM; Wu DP; He J
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):829-34. PubMed ID: 23384905
[TBL] [Abstract][Full Text] [Related]
5. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
Wen XM; Lin J; Yang J; Yao DM; Deng ZQ; Tang CY; Xiao GF; Yang L; Ma JC; Hu JB; Qian W; Qian J
Int J Clin Exp Pathol; 2014; 7(10):6832-40. PubMed ID: 25400766
[TBL] [Abstract][Full Text] [Related]
6. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.
Wang L; Xu WL; Meng HT; Qian WB; Mai WY; Tong HY; Mao LP; Tong Y; Qian JJ; Lou YJ; Chen ZM; Wang YG; Jin J
J Zhejiang Univ Sci B; 2010 Oct; 11(10):762-70. PubMed ID: 20872983
[TBL] [Abstract][Full Text] [Related]
7. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
8. Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia.
Reuter CW; Krauter J; Onono FO; Bunke T; Damm F; Thol F; Wagner K; Göhring G; Schlegelberger B; Heuser M; Ganser A; Morgan MA
Ann Hematol; 2014 Jun; 93(6):977-82. PubMed ID: 24737308
[TBL] [Abstract][Full Text] [Related]
9. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.
Bowen DT; Frew ME; Hills R; Gale RE; Wheatley K; Groves MJ; Langabeer SE; Kottaridis PD; Moorman AV; Burnett AK; Linch DC
Blood; 2005 Sep; 106(6):2113-9. PubMed ID: 15951308
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implication of N-RAS gene mutations in Egyptian adult acute myeloid leukemia.
Elghannam DM; Abousamra NK; Shahin DA; Goda EF; Azzam H; Azmy E; El-Din MS; El-Refaei MF
Egypt J Immunol; 2009; 16(1):9-15. PubMed ID: 20726318
[TBL] [Abstract][Full Text] [Related]
12. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia.
Nakagawa T; Saitoh S; Imoto S; Itoh M; Tsutsumi M; Hikiji K; Nakamura H; Matozaki S; Ogawa R; Nakao Y
Oncology; 1992; 49(2):114-22. PubMed ID: 1574246
[TBL] [Abstract][Full Text] [Related]
13. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
Paschka P; Du J; Schlenk RF; Gaidzik VI; Bullinger L; Corbacioglu A; Späth D; Kayser S; Schlegelberger B; Krauter J; Ganser A; Köhne CH; Held G; von Lilienfeld-Toal M; Kirchen H; Rummel M; Götze K; Horst HA; Ringhoffer M; Lübbert M; Wattad M; Salih HR; Kündgen A; Döhner H; Döhner K
Blood; 2013 Jan; 121(1):170-7. PubMed ID: 23115274
[TBL] [Abstract][Full Text] [Related]
14. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
Badar T; Patel KP; Thompson PA; DiNardo C; Takahashi K; Cabrero M; Borthakur G; Cortes J; Konopleva M; Kadia T; Bohannan Z; Pierce S; Jabbour EJ; Ravandi F; Daver N; Luthra R; Kantarjian H; Garcia-Manero G
Leuk Res; 2015 Dec; 39(12):1367-74. PubMed ID: 26547258
[TBL] [Abstract][Full Text] [Related]
15. N-ras mutations in 43 Chinese cases of acute myeloid leukemia.
Guo W; Tang B; Xu S; Yao Y; Ye D
Chin Med J (Engl); 1998 Apr; 111(4):343-5. PubMed ID: 10374400
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
[TBL] [Abstract][Full Text] [Related]
17. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
[TBL] [Abstract][Full Text] [Related]
18. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
[TBL] [Abstract][Full Text] [Related]
19. Frequent coexistence of RAS mutations in RUNX1-mutated acute myeloid leukemia in Arab Asian children.
Al-Kzayer LF; Sakashita K; Al-Jadiry MF; Al-Hadad SA; Uyen le TN; Liu T; Matsuda K; Abdulkadhim JM; Al-Shujairi TA; Matti ZI; Hasan JG; Al-Abdullah HM; Inoshita T; Kamata M; Sughayer MA; Madanat FF; Koike K
Pediatr Blood Cancer; 2014 Nov; 61(11):1980-5. PubMed ID: 25066867
[TBL] [Abstract][Full Text] [Related]
20. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.
Balgobind BV; Hollink IH; Arentsen-Peters ST; Zimmermann M; Harbott J; Beverloo HB; von Bergh AR; Cloos J; Kaspers GJ; de Haas V; Zemanova Z; Stary J; Cayuela JM; Baruchel A; Creutzig U; Reinhardt D; Pieters R; Zwaan CM; van den Heuvel-Eibrink MM
Haematologica; 2011 Oct; 96(10):1478-87. PubMed ID: 21791472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
